Stonvex publishes market data and research only. Not investment advice. Not a registered investment advisor. Read disclaimer.

TRDA

Live52w low +23.7%

Annual Quarterly

Core line items from TRDA's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

Log in Get Started

Annual Quarterly

Financial statements

Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.

Entity: ENTRADA THERAPEUTICS, INC.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-04	Q1 2026 2026-03-31	Annual 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30
Revenue	$149.60K	$875.00K	$25.42M	$24.12M	$22.51M
Operating Income	Not available	$-42.30M	$-157.90M	$-115.69M	$-68.64M
Net Income	Not available	$-39.72M	$-143.75M	$-104.59M	$-43.10M
EPS (Diluted)	$-1.09	$-0.95	$-3.47	$-2.53	$-1.47
Total Assets	Not available	$335.52M	$377.38M	$412.90M	$448.78M
Total Liabilities	Not available	$64.66M	$71.25M	$72.18M	$69.28M
Cash & Equivalents	Not available	$76.44M	$90.39M	$93.29M	$72.48M
Free Cash Flow OCF − CapEx	Not available	$-41.74M	$-129.55M	$-97.56M	$-69.42M
Shares Outstanding	Not available	38.82M	38.28M	38.22M	38.03M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.

Core line items from TRDA's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

52w low +23.7%

Financial statements

Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.

Entity: ENTRADA THERAPEUTICS, INC.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-04	Q1 2026 2026-03-31	Annual 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30
Revenue	$149.60K	$875.00K	$25.42M	$24.12M	$22.51M
Operating Income	Not available	$-42.30M	$-157.90M	$-115.69M	$-68.64M
Net Income	Not available	$-39.72M	$-143.75M	$-104.59M	$-43.10M
EPS (Diluted)	$-1.09	$-0.95	$-3.47	$-2.53	$-1.47
Total Assets	Not available	$335.52M	$377.38M	$412.90M	$448.78M
Total Liabilities	Not available	$64.66M	$71.25M	$72.18M	$69.28M
Cash & Equivalents	Not available	$76.44M	$90.39M	$93.29M	$72.48M
Free Cash Flow OCF − CapEx	Not available	$-41.74M	$-129.55M	$-97.56M	$-69.42M
Shares Outstanding	Not available	38.82M	38.28M	38.22M	38.03M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.